Drug profile · INN
emicizumab
HEMLIBRA
emicizumab (HEMLIBRA) is a coagulation factor ix and x other. Route of administration: injection. Current US regulatory status: approved.
Drug details — emicizumab
- US status
- approved
- Class
- Blood and blood forming organs (B02)
- Route
- INJECTION
- Patents
- 0
- Programs
- 6
- Data quality
- 0.84
Quick answer
emicizumab (HEMLIBRA) is a coagulation factor ix and x other. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Coagulation factor IX and X other
Primary target: Coagulation factor IX and X
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is emicizumab?
emicizumab (HEMLIBRA) is a coagulation factor ix and x other. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for emicizumab?
HEMLIBRA is a marketed brand name for emicizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of emicizumab?
emicizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.